Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dementia l: Introduction01:22

Dementia l: Introduction

35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35
Dementia01:30

Dementia

693
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
693
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

34
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
34
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

28
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of...
28
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

29
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
29
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daridorexant: A new medication for insomnia in older adults?

Neurology·2020
Same author

Author response: Burnout, career satisfaction, and well-being among US neurology residents and fellows in 2016.

Neurology·2018
Same author

Burnout, career satisfaction, and well-being among US neurology residents and fellows in 2016.

Neurology·2017
Same author

Hormone therapy and brain structure in postmenopausal women.

Neurology·2016
Same author

Treatment and Management of Dementia Due to Alzheimer's Disease.

Current treatment options in neurology·2015
Same author

Coding for sleep disorders.

Continuum (Minneapolis, Minn.)·2013

Related Experiment Video

Updated: May 6, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K

Dementia with Lewy bodies.

Jennifer Rose V Molano1

  • 1Department of Neurology and Rehabilitation Medicine, The University of Cincinnati College of Medicine, Cincinnati, Ohio.

Seminars in Neurology
|November 16, 2013
PubMed
Summary

Dementia with Lewy bodies (DLB) is a distinct neurodegenerative disease causing cognitive decline and motor symptoms. Research is exploring its genetic basis to identify at-risk individuals before cognitive symptoms emerge.

Area of Science:

  • Neuroscience
  • Neurology
  • Pathology

Background:

  • Dementia with Lewy bodies (DLB) is a synucleinopathy.
  • It presents distinct clinical features including cognitive decline, fluctuating alertness, visual hallucinations, and parkinsonism.
  • Associated symptoms include dysautonomia and REM sleep behavior disorder (RBD).

Purpose of the Study:

  • To differentiate DLB from Alzheimer's disease.
  • To understand the pathological criteria of DLB.
  • To explore the genetic basis of DLB and identify at-risk individuals.

Main Methods:

  • Clinical assessment of DLB symptoms.
  • Pathological examination of Lewy body and Alzheimer's pathology.
  • Genetic studies to investigate DLB etiology.

More Related Videos

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors
05:18

Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors

Published on: January 21, 2017

7.7K

Related Experiment Videos

Last Updated: May 6, 2026

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
12:28

Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains

Published on: June 3, 2020

18.2K
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

11.4K
Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors
05:18

Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors

Published on: January 21, 2017

7.7K

Main Results:

  • DLB is pathologically defined by Lewy body distribution and co-existing Alzheimer's pathology.
  • Current treatments for DLB are symptomatic.
  • The genetic underpinnings of DLB are under investigation.

Conclusions:

  • DLB is a distinct clinical and pathological entity.
  • Future research aims to develop predictive markers for DLB risk.
  • Early identification strategies are crucial for potential interventions.